Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Fusen Pharmaceutical Company Limited has issued a profit warning, expecting a loss of RMB 30 to 45 million for the first half of 2024, a stark contrast to the RMB 16.5 million profit in the same period of the previous year. The anticipated loss is primarily due to a substantial 40% drop in revenue, influenced by market demand and increased investments in research and development. The company advises shareholders and potential investors to approach dealings with caution and look forward to the official interim results announcement on 29 August 2024.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.